Coronavirus (COVID-19) Vaccine Update
Click here to learn more.
For information about COVID-19 or to view additional resources, please
Primary objective:To compare the overall survival (OS) in patients with metastatic RCC treated with ipilimumabnivolumab followed by either nivolumab versus cabozantinib-nivolumab.
Jianqing Lin, MD